Minoxidil vs PT-141
FDA Approved vs FDA Approved
monitor Mechanism-based · 60% Both Minoxidil and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Minoxidil PT-141
Weight 209.25 Da —
Half-life ~4 hours (oral); topical effects persist significantly longer due to local tissue retention ~2.7 hours
Type Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine) Melanocortin receptor agonist
Key Benefits
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Minoxidil
Topical: 1mL of 5% solution twice daily / Oral: 1.25-2.5mg daily / Twice daily (topical) or once daily (oral)
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Minoxidil PT-141
Status FDA Approved FDA Approved
References 5 studies 4 studies
Latest — 2022
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.